REG - Hemogenyx Pharma Plc - Placing to Raise US$4.2 million

Hemogenyx PharmaceuticalsAnnouncement

29/02/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240229:nRSc8655Ea&default-theme=true

RNS Number : 8655E  Hemogenyx Pharmaceuticals PLC  29 February 2024

29 February 2024

 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO, OR TO ANY PERSON
LOCATED OR RESIDENT IN, ANY JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE,
PUBLISH OR DISTRIBUTE THIS ANNOUNCEMENT. THIS ANNOUNCEMENT CONTAINS INSIDE
INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATIONS (EU)
NO. 596/2014 WHICH FORMS PART OF DOMESTIC UK LAW PURSUANT TO THE EUROPEAN
UNION (WITHDRAWAL) ACT 2018 ("UK MAR").

 

MARKET SOUNDINGS WERE TAKEN IN RESPECT OF THE MATTERS CONTAINED IN THIS
ANNOUNCEMENT, WITH THE RESULT THAT CERTAIN PERSONS BECAME AWARE OF SUCH INSIDE
INFORMATION. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE
INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN AND SUCH PERSONS
SHALL THEREFORE CEASE TO BE IN POSSESSION OF INSIDE INFORMATION.

 

Hemogenyx Pharmaceuticals plc

 

("Hemogenyx Pharmaceuticals" or the "Company")

 

Placing to Raise US$4.2 million

 

Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group
developing new therapies and treatments for blood diseases, is pleased to
announce that it has successfully raised US$4.2 million (£3.325 million)
before expenses through the allotment and issue of 166,250,000 new ordinary
shares at 2 pence per share (the "Placing", "Placing Shares").

 

The net proceeds from the Placing will be used to facilitate the development
of the Company's Chimeric Antigen Receptor T-cells ("HEMO-CAR-T") for the
treatment of acute myeloid leukaemia ("AML"). As announced on 9 February 2024,
the Company was informed by the U.S. Federal Food and Drug Administration
("FDA") that it had lifted the clinical hold on the Investigational New Drug
("IND") application for HEMO-CAR-T for the treatment of AML. The funds have
been raised to allow the Company to progress HEMO-CAR-T to phase 1 clinical
trials.

 

An application is being made to the London Stock Exchange Main Market and
admission of the Placing Shares to trading is expected on or around 6 March
2024 ("Admission"). The Placing Shares will rank pari passu with the
existing ordinary shares in the Company.

 

Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals,
commented:

"We are extremely pleased to have raised these funds to allow us to progress
our lead asset, HEMO-CAR-T, to clinical trials. This is a key development that
represents the progression of Hemogenyx Pharmaceuticals to become a clinical
stage company and the fundraise was crucial to enable us to progress toward
clinical trials, the essential next step for the development of HEMO-CAR-T. I
would like to thank new and existing shareholders for their support and for
contributing to this sizeable fundraise in difficult market conditions. The
recent lifting of the clinical hold by the FDA on our HEMO-CAR-T programme
followed a great effort from everyone at Hemogenyx Pharmaceuticals for which I
am very grateful."

 

Total Voting Rights

 

For the purpose of the Disclosure Guidance and Transparency Rules, following
Admission the enlarged issued share capital of the Company will comprise
1,341,815,988 ordinary shares. The Company does not hold any shares in
treasury. The above figure may be used by shareholders as the denominator for
the calculations by which they will determine if they are required to notify
their interest in, or a change to their interest in, the Company, under the
Disclosure Guidance and Transparency Rules.

 

For the purposes of UK MAR, the person responsible for arranging for the
release of this Announcement on behalf of the Company is Dr Vladislav Sandler,
Chief Executive Officer & Co-Founder.

 

Enquiries:

 Hemogenyx Pharmaceuticals plc                                   https://hemogenyx.com (https://hemogenyx.com/)
 Dr Vladislav Sandler, Chief Executive Officer & Co-Founder      headquarters@hemogenyx.com (mailto:headquarters@hemogenyx.com)
 Peter Redmond, Director                                         peter.redmond@hemogenyx.com (mailto:peter.redmond@hemogenyx.com)
 SP Angel Corporate Finance LLP                                  Tel: +44 (0)20 3470 0470
 Matthew Johnson, Vadim Alexandre, Adam Cowl
 Peterhouse Capital Limited                                      Tel: +44 (0)20 7469 0930
 Lucy Williams, Duncan Vasey, Charles Goodfellow

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO)
headquartered in London, with its US operating subsidiaries, Hemogenyx
Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its
state-of-the-art research facility.

 

The Company is a pre-clinical stage biopharmaceutical group developing new
medicines and treatments to treat blood and autoimmune disease and to bring
the curative power of bone marrow transplantation to a greater number of
patients suffering from otherwise incurable life-threatening diseases.
Hemogenyx Pharmaceuticals is developing several distinct and complementary
product candidates, as well as platform technologies that it uses as engines
for novel product development.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEUWVWRSKUUUAR